District Court Rules DNA Analysis Claims Reciting Mathematical Algorithms Ineligible Under § 101

Oct 26, 2020

Reading Time : 3 min

The Cybergenetics patents at issue—U.S. Patent Nos. 8,898,021 and 9,708,642—describe a variation of a traditional method of identifying an individual based on a DNA sample. The traditional method uses “PCR (polymerase chain reaction) amplification” to transform the DNA sample into data that are unique to an individual and thus can be used to identify that individual. The method is not useful, however, when the sample contains DNA from multiple sources because the transformed data are “mixed” and do not correspond to one individual.

The patents address that problem by employing what they call “deconvolution”—a process that accounts for multiple individuals in a DNA sample by “calculating the variance of the DNA data produced by PCR amplification and accounting for that variance in subsequent probability calculations.” The probability calculations “predict the identity of an individual in the sample and calculate the likelihood that the prediction is correct.” In other words, the patented methods determine the likelihood that a given individual’s DNA is contained in a sample instead of merely identifying one individual.

Cybergenetics asserted several claims of these patents against the Institute of Environmental Science and Research, and NicheVision Inc., based on their alleged use of “deconvolution” technology. The court granted the defendants’ motion to dismiss after determining that the asserted claims fail both steps of the Alice framework.

Under step one, the court explained that the Cybergenetics claims “recite mathematical algorithms to produce a numerical output as the entirety of the method.” In particular, the claimed “deconvolution” process “describes the process of calculating a variance (a numerical result) and then accounting for that variance in subsequent statistical calculations (also numerical results).” The court further explained that the U.S. Supreme Court and Federal Circuit have repeatedly held that mathematical algorithms are examples of abstract ideas. It then found that the use of algorithms is “⁠[t]he only difference between” conventional methods and the claimed methods, further showing that the claims are “directed to” such abstract ideas.

The court rejected Cybergenetics’ argument that the asserted claims were akin to those analyzed in the Federal Circuit’s Thales, McRO and CardioNet cases in which claims survived Alice challenges despite reciting mathematical algorithms. The court explained that the mathematical algorithms in those cases “were used as part of a non-mathematical process” (emphasis added). For example, in Thales, a mathematical algorithm and its result were used “to track the position and orientation of [an] object.” In McRO, an algorithm was used to “generate a tangible product, namely a video of a 3-D character speaking [] recorded audio.” And in CardioNet, the claims improved the operation of a cardiac monitoring machine, albeit through the use of an algorithm. Unlike in those cases, “the numerical result” in the Cybergenetics claims is the claimed “improvement,” and the numerical result is not used for any “non-mathematical process.”

Under step two, the court explained that the Cybergenetics claims fail to recite an “inventive concept” because they do not recite any “elements other than the computation of mathematical algorithms and reporting the numerical results.” Specifically, some claims merely recite mathematical algorithms, some recite a generic computer that calculates the mathematical algorithms (or merely display the results of such calculations) and some recite the conventional step of using “PCR amplification” to transform a DNA sample into data. According to the court, all three categories of claims “capture patent-ineligible ideas.” 

The court rejected the argument that the “inventive concept” is a specific application of a mathematical technique to “computer-based DNA analysis” or to “probabilistic genotyping.” As the court explained, “[c]ourts have consistently rejected finding a claim provides an inventive concept simply because it is limited ‘to one field of use.’”

Practice Tip: After six years, courts continue to use Alice to dismiss patent claims directed to so-called “abstract ideas.” The Cybergenetics case demonstrates the fine line between claims that are directed to a mathematical algorithm—one of the few things the higher courts have specifically identified as an “abstract idea”—and claims that merely use them. When possible, patentees should draft claims (and specifications) in a way that emphasizes tangible improvements even when achieving such improvements requires using a mathematical algorithm. By the same token, defendants should consider attacking any patent claims that rely on a mathematical algorithm, and they should try to characterize that algorithm as the focus of the patent and the claims. The Cybergenetics case will certainly be one worth monitoring on appeal (if there is one) to see if the Federal Circuit agrees with the district court’s analysis.

Cybergenetics Corp. v. Institute of Environmental Science and Research, 5:19-cv-1197 (N.D. Ohio Sep. 29, 2020) (Lioi, J.)

Share This Insight

Previous Entries

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.